HALEOS Labs Analyst Review May 2026
- May 20, 2026
- Posted by: Kashish Aggarwal
- Category: News
This HALEOS Labs analyst review for May 2026 covers the key data investors need for HALEOS Labs at its current price of Rs 225. HALEOS Labs (NSE: HALEOLABS) is a healthcare diagnostics and technology company with a market capitalisation of approximately Rs 600 crore. The analyst consensus target of Rs 260 implies meaningful upside, and this HALEOS Labs analyst review examines technical levels, business segments, valuation, and key risks for HALEOLABS through FY27.
Click Here – Get Free Investment Predictions
HALEOS Labs Company Snapshot May 2026
HALEOS Labs provides diagnostic services, laboratory information systems, and healthcare analytics platforms. The digitisation of Indian healthcare diagnostics and telemedicine growth are structural demand drivers. The table below summarises the key data referenced in this HALEOS Labs analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | HALEOLABS |
| Sector | Diagnostics and Healthcare Technology |
| CMP (May 2026) | Rs 225 |
| 52 Week High | Rs 318 |
| 52 Week Low | Rs 165 |
| Market Cap | Rs 600 Crore |
| Trailing P/E | NAx |
| Analyst Consensus Target | Rs 260 |
| Bull Case Target | Rs 330 |
| Bear Case Target | Rs 160 |
Analyst Insight in This HALEOS Labs Analyst Review
Senior Research Analyst Ankit Jaiswal flags HALEOS Labs as a stock to watch in May 2026. At Rs 225, Ankit Jaiswal identifies key support in the Rs 168 to Rs 214 band and resistance near Rs 238. He suggests watching HALEOS Labs for a potential move toward Rs 260, subject to Diagnostics and Healthcare Technology sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this HALEOS Labs analyst review and does not constitute a trade recommendation.
Technical Analysis in This HALEOS Labs Analyst Review
At Rs 225, HALEOLABS is trading within its 52-week band of Rs 165 to Rs 318. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 168 to Rs 214 band while resistance is seen in the Rs 238 to Rs 242 zone. A sustained move above Rs 238 could open the path toward the analyst consensus target of Rs 260 as outlined in this HALEOS Labs analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 168 to Rs 214 – investors tracking this HALEOS Labs analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for HALEOLABS.
- Resistance Zone: Rs 238 to Rs 242 – a sustained close above Rs 238 would be a positive breakout signal worth flagging in this HALEOS Labs analyst review.
- Medium-Term Target: The analyst consensus of Rs 260 represents the base-case upside scenario in this HALEOS Labs analyst review.
Business Segment Analysis
Diagnostic Laboratory Services
This is the primary revenue and margin driver for HALEOS Labs, directly supporting the earnings trajectory toward the consensus target of Rs 260.
Healthcare IT and Laboratory Information Systems
This segment adds scale and diversification to HALEOS Labs’s business model and is a meaningful EPS contributor through FY27 and FY28.
Telemedicine and Remote Diagnostics
This represents the medium-term growth frontier for HALEOS Labs and a key re-rating catalyst over the next 12 to 24 months.
Valuation in This HALEOS Labs Analyst Review
At Rs 225, HALEOS Labs trades at a trailing P/E of NAx. This HALEOS Labs analyst review presents three scenarios: a bull case of Rs 330 on strong earnings delivery and sector tailwinds, a base case of Rs 260 at analyst consensus, and a bear case of Rs 160 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this HALEOS Labs analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 330 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 260 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 160 | Earnings miss or macro headwinds |
Trade Outlook for HALEOS Labs
Based on the technical and fundamental analysis in this HALEOS Labs analyst review, investors might watch HALEOLABS near the support zone of Rs 168 to Rs 214 for potential opportunities. A flag above Rs 238 could suggest improving momentum toward Rs 260. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for HALEOS Labs in FY27
A well-rounded HALEOS Labs analyst review must assess downside risks. Key risks for HALEOS Labs include a macro slowdown affecting Diagnostics and Healthcare Technology sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in HALEOLABS.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: HALEOS Labs Analyst Review Verdict for 2026
This HALEOS Labs analyst review concludes that at Rs 225, HALEOLABS offers a defined risk-reward with a consensus target of Rs 260. The 52-week range of Rs 165 to Rs 318 provides context on the current entry point. Use this HALEOS Labs analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on HALEOLABS.
Frequently Asked Questions: HALEOS Labs Analyst Review 2026
What is the analyst’s target for HALEOS Labs in 2026?
The analyst consensus target is Rs 260, with a bull case of Rs 330 and a bear case of Rs 160. This HALEOS Labs analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is HALEOS Labs a good investment at Rs 225?
At Rs 225 with a P/E of NAx and a consensus target of Rs 260, this HALEOS Labs analyst review is constructive for medium to long-term investors in the Diagnostics and Healthcare Technology sector. Always consult a SEBI-registered advisor before investing.
What is HALEOS Labs’s 52-week high and low?
The 52-week high is Rs 318 and the 52-week low is Rs 165. At Rs 225, HALEOLABS is positioned within this range as detailed in this HALEOS Labs analyst review.
What are the key risks for HALEOS Labs?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Diagnostics and Healthcare Technology sector, all assessed in this HALEOS Labs analyst review.
Where can I track live data for HALEOS Labs?
Track HALEOS Labs’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this HALEOS Labs analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
